Skip to main content
SpringerLink
Log in

Benign and Malignant Diseases of the Prostate

  • Living reference work entry
  • First Online:
Principles and Practice of Geriatric Surgery

  • 70 Accesses

Abstract

A significant number of people will experience urologic disease with age. The breath of urology covers the entire urinary tract along with the retroperitoneum and male genital structures. Herein, we discuss diseases of the kidney, bladder, and prostate with a particular focus in malignancies of these organ systems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479

    Article  CAS  PubMed  Google Scholar 

  2. Jacobsen SJ, Jacobson DJ, Girman CJ et al (1999) Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162:1301–1306

    Article  CAS  PubMed  Google Scholar 

  3. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS (2009) Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 57:24–30

    Article  PubMed  Google Scholar 

  4. Taylor JA 3rd, Kuchel GA (2006) Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 54:1920–1932

    Article  PubMed  Google Scholar 

  5. Roberts RO, Bergstralh EJ, Cunningham JM et al (2004) Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 159:269–276

    Article  PubMed  Google Scholar 

  6. Elbadawi A, Yalla SV, Resnick NM (1993) Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. J Urol 150:1650–1656

    Article  CAS  PubMed  Google Scholar 

  7. Malone-Lee J, Wahedna I (1993) Characterisation of detrusor contractile function in relation to old age. Br J Urol 72:873–880

    Article  CAS  PubMed  Google Scholar 

  8. Resnick NM, Yalla SV (1987) Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 257:3076–3081

    Article  CAS  PubMed  Google Scholar 

  9. Resnick NM, Yalla SV, Laurino E (1989) The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 320:1–7

    Article  CAS  PubMed  Google Scholar 

  10. Chaikin DC, Blaivas JG (2001) Voiding dysfunction: definitions. Curr Opin Urol 11:395–398

    Article  CAS  PubMed  Google Scholar 

  11. Su L, Guess HA, Girman CJ et al (1996) Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol 49:483–487

    Article  CAS  PubMed  Google Scholar 

  12. Davis R, Jones JS, Barocas DA, Castle EP et al (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol Suppl 188:2473

    Article  Google Scholar 

  13. Carroll PR, Parsons JK, Andriole G, Bahnson RR et al (2015) NCCN clinical practice guidelines prostate cancer early detection, version 2.2015. J Natl Compr Cancer Netw 13:1534

    Article  CAS  Google Scholar 

  14. Lepor H (1998) Phase III multicenter placebo-controlled study of Tamsulosin in benign prostatic hyperplasia. Urology 51:892–900

    Article  CAS  PubMed  Google Scholar 

  15. Hellstrom WJ, Sikka SC (2006) Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 176:1529–1533

    Article  CAS  PubMed  Google Scholar 

  16. Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, Hemerson P, Rogers M, Stamper B (2008) Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 42:558

    Article  CAS  PubMed  Google Scholar 

  17. McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557–563

    Article  CAS  PubMed  Google Scholar 

  18. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The veterans affairs cooperative study group on transurethral resection of the prostate. N Engl J Med 332:75–79

    Article  CAS  PubMed  Google Scholar 

  19. Geavlete B, Stanescu F, Iacoboaie C, Geavlete P (2013) Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases – a medium term, prospective, randomized comparison. BJU Int 111:793

    Article  CAS  PubMed  Google Scholar 

  20. Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69:363–385

    Article  PubMed  Google Scholar 

  21. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34

    Article  PubMed  Google Scholar 

  22. Edwards CN, Steinthorsson E, Nicholson D (1953) An autopsy study of latent prostatic cancer. Cancer 6:531–554

    Article  CAS  PubMed  Google Scholar 

  23. Smith JR, Freije D, Carpten JD et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (New York, NY) 274:1371–1374

    Article  CAS  Google Scholar 

  24. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17:337–347

    Article  CAS  PubMed  Google Scholar 

  25. Draisma G, De Koning HJ (2003) MISCAN: estimating lead-time and over-detection by simulation. BJU Int 92(Suppl 2):106–111

    Article  PubMed  Google Scholar 

  26. Byar DP, Mostofi FK (1972) Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 30:5–13

    Article  CAS  PubMed  Google Scholar 

  27. McNeal JE (1992) Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23:258–266

    Article  CAS  PubMed  Google Scholar 

  28. Gilliland F, Becker TM, Smith A, Key CR, Samet JM (1994) Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 3:105–111

    CAS  Google Scholar 

  29. Ellis WJ, Chetner MP, Preston SD, Brawer MK (1994) Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152:1520–1525

    Article  CAS  PubMed  Google Scholar 

  30. Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215–2220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948–954

    Article  CAS  PubMed  Google Scholar 

  32. Albertsen PC, Hanley JA, Harlan LC et al (2000) The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 163:1138–1143

    Article  CAS  PubMed  Google Scholar 

  33. Siddiqui MM, Rais-Bahrami S, Turkbey B et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313:390–397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Syed JS, Nguyen KA, Nawaf CB et al (2017) Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion-targeted biopsy in patients with a solitary PI-RADS v2-scored lesion. Urol Oncol 35:542.e19–24

    Article  Google Scholar 

  35. Sheridan AD, Nath SK, Aneja S et al (2018) MRI-ultrasound fusion targeted biopsy of prostate imaging reporting and data system version 2 category 5 lesions found false-positive at multiparametric prostate MRI. AJR Am J Roentgenol 210:W218–W225

    Article  PubMed  Google Scholar 

  36. Sheridan AD, Nath SK, Syed JS et al (2018) Risk of clinically significant prostate cancer associated with prostate imaging reporting and data system category 3 (equivocal) lesions identified on multiparametric prostate MRI. AJR Am J Roentgenol 210:347–357

    Article  PubMed  Google Scholar 

  37. Lu AJ, Syed JS, Nguyen KA et al (2017) Negative multiparametric magnetic resonance imaging of the prostate predicts absence of clinically significant prostate cancer on 12-core template prostate biopsy. Urology 105:118–122

    Article  PubMed  Google Scholar 

  38. Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777

    Article  PubMed  PubMed Central  Google Scholar 

  39. Syed JS, Javier-Desloges J, Tatzel S et al (2017) Current management strategy for active surveillance in prostate cancer. Curr Oncol Rep 19:11

    Article  PubMed  Google Scholar 

  40. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626–631

    Article  CAS  PubMed  Google Scholar 

  41. Chodak GW, Thisted RA, Gerber GS et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248

    Article  CAS  PubMed  Google Scholar 

  42. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132

    Article  CAS  PubMed  Google Scholar 

  43. Lu-Yao GL, Albertsen P, Warren J, Yao SL (1999) Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy–a population-based study. Urology 54:301–307

    Article  CAS  PubMed  Google Scholar 

  44. Eastham JA, Kattan MW, Rogers E et al (1996) Risk factors for urinary incontinence after radical prostatectomy. J Urol 156:1707–1713

    Article  CAS  PubMed  Google Scholar 

  45. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 42:622–629

    Article  PubMed  Google Scholar 

  46. Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 283:354–360

    Article  CAS  PubMed  Google Scholar 

  47. Quinlan DM, Epstein JI, Carter BS, Walsh PC (1991) Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 145:998–1002

    Article  CAS  PubMed  Google Scholar 

  48. Bill-Axelson A, Holmberg L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100:1144–1154

    Article  PubMed  PubMed Central  Google Scholar 

  49. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 181:956–962

    Article  PubMed  PubMed Central  Google Scholar 

  50. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930

    Article  PubMed  Google Scholar 

  51. Pinkawa M, Gagel B, Piroth MD, Fischedick K et al (2009) Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 55:227

    Article  PubMed  Google Scholar 

  52. Sun M, Sammon JD, Becker A, Roghmann F et al (2014) Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int 113:200

    Article  PubMed  Google Scholar 

  53. Flocks RH, Nelson CM, Boatman DL (1972) Perineal cryosurgery for prostatic carcinoma. J Urol 108:933

    Article  CAS  PubMed  Google Scholar 

  54. Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J (2008) Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 71:515

    Article  PubMed  Google Scholar 

  55. Chaussy CG, Thuroff S (2017) High-intensity focused ultrasound for the treatment of prostate cancer: a review. J Endourol 31:S-30

    Article  Google Scholar 

  56. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112:307

    Article  PubMed  Google Scholar 

  57. Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H (1999) Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol 162:1282–1284; discussion 4–5

    Article  CAS  PubMed  Google Scholar 

  58. Sivalingam S, Nakada SY (2013) Contemporary minimally invasive treatment options for renal angiomyolipomas. Curr Urol Rep 14:147

    Article  PubMed  Google Scholar 

  59. Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78

    Article  PubMed  Google Scholar 

  60. Dhote R, Thiounn N, Debre B, Vidal-Trecan G (2004) Risk factors for adult renal cell carcinoma. Urol Clin North Am 31(2):237–247

    Article  CAS  PubMed  Google Scholar 

  61. Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM (1999) Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162(4):1246–1258

    Article  CAS  PubMed  Google Scholar 

  62. Gnarra JR, Tory K, Weng Y, Schmidt L et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7(1):85–90

    Article  CAS  PubMed  Google Scholar 

  63. Bosniak MA (1995) Observation of small incidentally detected renal masses. Semin Urol Oncol 13(4):267–272

    CAS  PubMed  Google Scholar 

  64. Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20(2):247–262

    CAS  PubMed  Google Scholar 

  65. Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51(2):203–205

    Article  CAS  PubMed  Google Scholar 

  66. Ritchie AW, Chisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10(4):390–400

    CAS  PubMed  Google Scholar 

  67. Syed JS, Nguyen KA, Holford TR, Hofmann JN, Shuch B (2019) Risk factors for metachronous bilateral renal cell carcinoma: a surveillance, epidemiology, and end results analysis. Cancer 15:125(2):232–238

    Article  CAS  Google Scholar 

  68. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628–1631

    Article  CAS  PubMed  Google Scholar 

  69. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170(6 Pt 1):2217–2220

    Article  PubMed  Google Scholar 

  70. Syed JS, Nawaf CB, Rosoff J, Bryson C et al (2017) Adverse pathologic characteristics in the small renal mass: implications for active surveillance. Can J Urol 24(2):8759–8764

    PubMed  Google Scholar 

  71. Syed JS, Lebacle C, Shuch B (2019) Barriers to pre-treatment genomic characterization of the small renal mass. Oncotarget 10(18):1667–1668

    Article  PubMed  PubMed Central  Google Scholar 

  72. Washburn ZW, Dillman JR, Cohan RH, Caoili EM, Ellis JH (2009) Computed tomographic urography update: an evolving urinary tract imaging modality. Semin Ultrasound CT MR 30(4):233–245

    Article  PubMed  Google Scholar 

  73. Mulholland SG, Stefanelli JL (1990) Genitourinary cancer in the elderly. Am J Kidney Dis 16(4):324–328

    Article  CAS  PubMed  Google Scholar 

  74. Bosniak MA (1997) The use of the Bosniak classification system for renal cysts and cystic tumors J Urol 157(5):1852–1853

    Article  CAS  PubMed  Google Scholar 

  75. Davidson AJ, Hartman DS, Choyke PL, Wagner BJ (1997) Radiologic assessment of renal masses: implications for patient care. Radiology 202(2):297–305

    Article  CAS  PubMed  Google Scholar 

  76. Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108

    Article  CAS  PubMed  Google Scholar 

  77. Blom JH, van Poppel H, Marechal JM, Jacqmin D et al (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 55(1):28–34

    Article  PubMed  Google Scholar 

  78. Crispen PL, Breau RH, Allmer C, Lohse CM et al (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59(1):18–23

    Article  PubMed  Google Scholar 

  79. Meraney AM, Gill IS (2002) Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol 167(4):1757–1762

    Article  PubMed  Google Scholar 

  80. Eden CG, Haigh AC, Carter PG, Coptcoat MJ (1994) Laparoscopic nephrectomy results in better postoperative pulmonary function. J Endourol 8(6):419–422

    Article  CAS  PubMed  Google Scholar 

  81. Najarian JS, Chavers BM, McHugh LE, Matas AJ (1992) 20 years or more of follow-up of living kidney donors. Lancet 340(8823):807–810

    Article  CAS  PubMed  Google Scholar 

  82. Huang WC, Levey AS, Serio AM, Snyder M et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7(9):735–740

    Article  PubMed  PubMed Central  Google Scholar 

  83. Castilla EA, Liou LS, Abrahams NA, Fergany A et al (2002) Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 60(6):993–997

    Article  PubMed  Google Scholar 

  84. Becker A, Ravi P, Roghmann F et al (2014) Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. Urology 83(6):1285–1291

    Article  PubMed  Google Scholar 

  85. Balducci L (2009) Supportive care in elderly cancer patients. Curr Opin Oncol 21(4):310–317

    Article  PubMed  Google Scholar 

  86. Motzer RJ, Escudier B, Oudard S, Hutson TE et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456

    Article  CAS  PubMed  Google Scholar 

  87. Gore ME, Szczylik C, Porta C, Bracarda S et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763

    Article  CAS  PubMed  Google Scholar 

  88. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  89. Prout GR Jr, Wesley MN, Yancik R, Ries LAG, Havlik RJ, Edwards BK (2005) Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 104(8):1638–1647

    Article  PubMed  Google Scholar 

  90. Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A (1989) The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141(2):350–355

    Article  CAS  PubMed  Google Scholar 

  91. Ro JY, Staerkel GA, Ayala AG (1992) Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19(3):435–453

    CAS  PubMed  Google Scholar 

  92. Allard P, Bernard P, Fradet Y, Tetu B (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81(5):692–698

    Article  CAS  PubMed  Google Scholar 

  93. Droller MJ (1992) Treatment of regionally advanced bladder cancer. An overview. Urol Clin North Am 19(4):685–693

    CAS  PubMed  Google Scholar 

  94. Thrasher JB, Crawford ED (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149(5):957–972

    Article  CAS  PubMed  Google Scholar 

  95. Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD (1986) Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135(5):920–922

    Article  CAS  PubMed  Google Scholar 

  96. Holmang S, Hedelin H, Anderstrom C, Johansson SL (1995) The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153(6):1823–1826; discussion 1826–1827

    Article  CAS  PubMed  Google Scholar 

  97. Prout GR Jr, Wesley MN, Yancik R, Ries LAG, Havlik RJ, Edwards BK (1987) The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 138(4):766–770

    Article  PubMed  Google Scholar 

  98. Peyromaure M, Zerbib M (2004) T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 93(1):60–63

    Article  CAS  PubMed  Google Scholar 

  99. Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167(4):1573–1583

    Article  PubMed  Google Scholar 

  100. Esrig D, Freeman JA, Stein JP, Skinner DG (1997) Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 15(3):154–160

    CAS  PubMed  Google Scholar 

  101. Sylvester RJ, Oosterlinck W, Holmang S et al (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa–pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69:231–244

    Article  PubMed  Google Scholar 

  102. Chang SS, Bochner BH, Chou R et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198(3):552–559

    Article  PubMed  PubMed Central  Google Scholar 

  103. Chamie K, Hu B, Devere White RW, Ellison LM (2008) Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int 102(3):284–290

    Article  PubMed  Google Scholar 

  104. Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y et al (2007) Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51(3):699–706

    Article  PubMed  Google Scholar 

  105. Weizer AZ, Joshi D, Daignault S, Kinnaman M et al (2007) Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 177(4):1287–1293

    Article  PubMed  Google Scholar 

  106. Roehrborn CG, Sagalowsky AI, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146(1):36–39

    Article  CAS  PubMed  Google Scholar 

  107. Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6(2):113–126

    Article  CAS  PubMed  Google Scholar 

  108. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    Article  PubMed  Google Scholar 

  109. Bamias A, Efstathiou E, Moulopoulos LA, Gika D et al (2005) The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16(2):307–313

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Yale University School of Medicine, New Haven, CT, USA

    Jamil Syed & Preston Sprenkle

Authors
  1. Jamil Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Preston Sprenkle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jamil Syed .

Editor information

Editors and Affiliations

  1. VA Connecticut Health Care System, Yale University School of Medicine, West Haven, CT, USA

    Ronnie A. Rosenthal

  2. SUNY Downstate School of Public Health, National Capital Region Johns Hopkins Medicine, Bethesda, MD, USA

    Michael E. Zenilman

  3. Center for Geriatric Surgery, Sinai Hospital of Baltimore, Baltimore, MD, USA

    Mark R. Katlic

Section Editor information

  1. Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA

    Jason Johanning

  2. Duke Medicine, Durham, NC, USA

    Sandhya Lagoo-Deenadayalan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Syed, J., Sprenkle, P. (2020). Benign and Malignant Diseases of the Prostate. In: Rosenthal, R., Zenilman, M., Katlic, M. (eds) Principles and Practice of Geriatric Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-20317-1_79-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20317-1_79-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20317-1

  • Online ISBN: 978-3-319-20317-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation